The nicotine-specific antibodies produced in rats by NicVAX also significantly reduced the effects of the nicotine on both blood pressure and heart rate. If people found tobacco less rewarding, they would be less likely to continue using it. NicVAX is proposed as a therapy that could enhance current treatments for nicotine addiction by helping smokers who are trying to kick the habit resist the urge to light up. A treatment program involving NicVAX might also include elements of cognitive-behavioral therapy and medication, such as bupropion, to help reduce withdrawal symptoms. However, the vaccine may have implications beyond simple nicotine addiction.
Smoking is known to increase the use of other addictive substances, such as heroin and cocaine.
Blocking the urge to smoke in those addicted to other substances, said Leshner, could prove to be a valuable tool in combating addictions to other drugs. That line of research, however, will certainly be pursued, he said, if clinical trials tith NicVAX prove promising in humans.